Year archive

Sandoz Group AG — 2025 filings

All 26 regulatory filings released by Sandoz Group AG (SDZ) in 2025, sourced directly from the official regulator.

26 Filings

2025 Period

2025 filings (26)

Filing	Released	Lang
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership M&A Activity	2025-12-08	English
Sandoz completes strategic acquisition of Just-Evotec Biologics EU SAS, asserting biosimilars leadership M&A Activity	2025-12-08	English
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients Regulatory Filings	2025-12-01	English
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients Regulatory Filings	2025-12-01	English
Sandoz launches Afqlir (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases Regulatory Filings	2025-11-24	English
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases Regulatory Filings	2025-11-24	English
Sandoz launches TYRUKO (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar Regulatory Filings	2025-11-17	English
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab M&A Activity	2025-11-12	English
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab M&A Activity	2025-11-12	English
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse M&A Activity	2025-11-04	English
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse M&A Activity	2025-11-04	English
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded Earnings Release 9M 2025	2025-10-30	English
Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded Earnings Release 9M 2025	2025-10-30	English
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar Legal Proceedings Report	2025-09-09	English
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar Legal Proceedings Report	2025-09-09	English
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options Regulatory Filings	2025-08-28	English
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options Regulatory Filings	2025-08-28	English
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations Environmental & Social Information	2025-08-12	English
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Interim / Quarterly Report H1 2025	2025-08-07	English
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach Capital/Financing Update	2025-07-01	English
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] Regulatory Filings	2025-06-02	English
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars Regulatory Filings	2025-05-21	English
Sandoz reports strong FY 2024 results and Q4 2024 sales Earnings Release FY 2024	2025-03-05	English
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] Regulatory Filings	2025-02-24	English
Francisco Ballester to retire; Peter Stenico appointed President Region International Board/Management Information	2025-02-03	English
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference Earnings Release 9M 2024	2025-01-14	English